Watching a monkey fook a football gets expensive when you are betting on getting it over the goal line.

4th of July celebration to be extended event in 2022

2 drinks is my limit. Thanks y'all. LOL

Colorado translation in honor of Mr Chuck Thompson: "Ain't the Macallan on Ice!"

Hopefully just the beginning of good news DR. This feels good for many of us but I am especially glad for you. Best to ya, Bud!

Volume was outstanding today! We'll handle price Monday. Have a great weekend, ya'all.

I continue to buy as the price drops. I believe in the clinical trial results and therefore the legitimate value of hemostyp.
I'd prefer the CEO took a personal loan rather than sell stock but I'm still a buyer. I often judge whether I'm being smart or foolish. I think we will find out relatively soon. Good luck, y'all!

Wow service, you really think "a HUNDRED DOLLARS a share" is possible? Let's go UEEC!

All signs point to approval in relatively short time so that line of reasoning just doesn't hold up

Trying to apply TA to this stock is ridiculous. It's value is solely determined by the marketability of hemostyp products which require FDA approval to maximize.Of course the time it takes to get that approval has an affect on stock holders' optimism. This is awfully straight forward and simple to understand. You use that chart only to entice scared holders to sell at low levels.

The slow pace of progress with this company's only product is frustrating for us all. May I suggest concentrating on your family and friends during this holiday season. That's what is really important. Money is necessary but don't let it rule your life - it's still just money. Getting upset over a message board is a waste. Best wishes to you all.

United Health Products HemoStyp(R) Gauze Advances to FDA Substantive Review
8:10 AM ET 5/5/21 | BusinessWire
HENDERSON, Nev.--(BUSINESS WIRE)--May 05, 2021--

https://www.unitedhealthproductsinc.com/press-releases/2021/5/5/united-health-products-hemostyp-gauze-advances-to-fda-substantive-review

Good morning, ya'all

You know what's really funny, even at .88 I have capital gains concerns

Wave, what I found refreshing was the communication from mgmnt. Thought that was clear enough. You getting ahead of me on the scotch, Bud?

Yes sir, DR. I just found it newsworthy that mgmnt was updating communication with FDA. Very refreshing

Just a blurb from the 10-k:

On March 3, 2021 we participated in a discussion with the Food & Drug Administration (“FDA”) regarding our Premarket Approval (“PMA”) application,
wherein the FDA requested supplemental information relating to our manufacturing procedures, including quality control related documentation. The FDA also
commented that the form and content of our clinical and non-clinical data has been evaluated and were satisfactory for them to complete their review process once
our application was finalized. We are collecting the requested information and incorporating these materials into our PMA application and will to resubmit to the
FDA once completed. There can be no assurance that our application, once revised and resubmitted, will lead to a successful FDA decision regarding a PMA

It's your day Wave. Drinks are on me. Congrats

Dang Wave. Been a standoff for over an hour on a .03 spread. Looking good for you unless...

Everything I own is up today! Looking forward to a great week. LOL

Thanks for the post Wave. Not sure my theory is 100% useless. Obviously there are other factors. You put a lot more effort into it than I did. Looks like buyers were fairly optimistic Jan 15 also.

Over 200K shares traded today, avg is 100K. You think it is becoming SOP to buy in on Fri for Mon PMA update? Then if it doesn't come sell some shares and play other short term opportunities til Friday again? Just a thought

Step 1: Hello, my name is BFU and I own UEEC
Etc

United Health Products Obtains International Patent Protection Measures for HemoStyp(R) Hydrocolloid
8:00 AM ET 2/17/21 | BusinessWire
HENDERSON, Nev.--(BUSINESS WIRE)--February 17, 2021--

United Health Products, Inc. (OTC: UEEC), ("UHP" or the "Company"), developer of HemoStyp, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent, today announced the publication under the Patent Cooperation Treaty of its international patent application relating to any hydrocolloid format of HemoStyp.

The Patent Cooperation Treaty ("PCT") is an international patent law treaty which provides a unified procedure for filing a patent application in most foreign countries. The Company previously filed provisional patent applications for its HemoStyp gauze and the hydrocolloid process in July 2020 and 2019, respectively.

On February 11, 2021, the Company was notified that its application to establish global patent protection for the process of creating and deploying a hydrocolloid (or gel) format of its previously patented HemoStyp hemostatic gauze was accepted for publication under the procedures of the PCT. This application largely duplicates the U.S. patent #62875798 filed July 18, 2019 to protect this proprietary process and application in the U.S. market and which remains pending.

Accordingly, UHP now has up to one year to register specific patents in those countries where it wishes to commercialize any future HemoStyp gel formats and will do so as its gel-related R&D activity progresses through the first half of 2021.

The Company's innovative hydrocolloid format, once approved for human surgical applications, will dramatically broaden the market opportunity for HemoStyp beyond what the current gauze and other solid formats can address. The gel format is well suited for specialized procedures such as spinal, vascular and laparoscopic surgeries.

Brian Thom, UHP's Chief Executive Officer, commented: "This publication is an important milestone in our effort to establish a global IP portfolio that will maximize the commercial value of our technology. While the U.S. Class III market remains our priority as we prepare for the commercial rollout of HemoStyp, we believe the international revenue potential for HemoStyp, particularly in gel format, is substantial."

About United Health Products --UHP develops patented wound care technologies; manufactures and markets hemostatic products for the healthcare and wound care sectors. The Company's main product, HemoStyp is an all-natural NORC designed to control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets.

For more information on the Company please visit: www.unitedhealthproductsinc.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005233/en/

If FDA approval is not forthcoming, perhaps we could sign Rodman up in reddit and see if he could persuade WSB guys to squeeze UEEC. Just a thought.

"Success is walking from failure to failure with no loss of enthusiasm."
-Winston Churchill, CCIV

Bought more today. Did PMA land as you predicted?

I can withstand anything but temptation - had to add 1000 more. Ready to apply Hemostyp to stock price ASAP

Whoa - over 400K shares traded at ascending price. Seems investors don't want to risk not being loaded for the long weekend.

UEEC has filed a patent for bleeding. It is pending

Interesting wording and timing.

Figured it was a legit institution, DR. Thanks for the confirmation.

About the Journal of Wound Care

Journal of Wound Care (JWC) is the definitive wound-care journal and the leading source of up-to-date research and clinical information on everything related to tissue viability. The journal was first launched in 1992 and caters to the needs of the multidisciplinary team. Published monthly, the journal’s international audience includes nurses, doctors and researchers specialising in wound management and tissue viability, as well as generalists wishing to enhance their practice.

JWC is the official journal of the World Union of Wound Care Societies (WUWHS) it is also the media partner of the European Wound Management Association (EWMA) and affiliated to over 40 other associations, societies and charities. In the United States JWC is affiliated with AAWC, NPUAP and APWH giving unrivaled access to the global wound care community.

JWC is the only monthly, international, Medline listed, impact factor journal available.

In addition to cutting edge and state-of-the-art research and practice articles, JWC also covers topics related to wound-care management, education and novel therapies, as well as JWC supplements, including dedicated bespoke educational supplements which support therapies, treatment options, scientific advances and medical evidence. These are hugely popular on a global scale. All articles are rigorously peer-reviewed by a panel of international experts, comprised of clinicians and researchers.

Specifically, JWC publishes:

High-quality evidence on all aspects of wound care, including leg ulcers, pressure ulcers, the diabetic foot, burns, surgical wounds, wound infection and more
The latest developments and innovations in wound care through both preclinical and preliminary clinical trials of potential new treatments worldwide
In-depth prospective studies of new treatment applications, as well as high-level research evidence on existing treatments
Clinical case studies providing information on how to deal with complex wounds
Comprehensive literature reviews on current concepts and practice, including cost-effectiveness
Updates on the activities of wound care societies around the world.
JWC is a global media platform for the dissemination of research and practice in the following additional mediums:

Events such as Wound Expo, The International Skin Integrity and Infection Prevention Conference and The JWC future of Tissue Viability event.
Intimate events such as round tables, focus groups and workshops
Position documents for the EWMA
Daily newspapers at key events in the calendar
Bespoke supplements and guides to therapies, practice and products
Directory publishing of wound care products

From 10-Q for 3/31/2019:

During the period ended March 31, 2019, 1,600,000 shares of common stock issued to Nate Knight who is the Chief Financial Officer of the Company, 500,000 shares of common stock issued to the office administrator, who is a person affiliated with the Company’s CEO and 50,000 shares of common stock issued to a Technical Product Supervisor, who is the son of the office administrator which had been held in escrow became vested by the Board of Directors. These shares had a fair market value of $1.09 per share at the date of issuance and $2,343,500 has been expensed during the three-month period ended March 31, 2019.

2:16 ET, 420k+ shares traded, 1.55/1.57 up 19% on the day. Looks like people don't want to be out of UEEC over the weekend!

$mile y'all

I'm not sure where this split talk is coming from and I don't see any basis for it, but I'd like to make a point for your consideration: If a stock is split in either direction your percentage of company ownership remains the same so your participation in a company buy-out is unchanged. However adding additional outstanding shares is dilutive to the value of each so each time it happens your share of the pie has shrunk. Just a fat man's thought.

Outstanding shares reported to OTC as of 9/16: 188,155,956. Increase of only 150,000 this time.

Transfer agent has not updated OTC on outstanding shares since 9/4. I have no idea if this means anything or not, but TA has updated daily for quite a while. Trust, but verify! LOL

https://www.otcmarkets.com/stock/UEEC/security

DR, I hope you realize that all of us have hoped that we would see the day when you got to say "I told you so." I also hope the payoff is substantial.

Best to you.

Thank you and csterner for your replies. I haven't time to go through 106 posts but perusing didn't quite answer my question. With UEEC I have decided to believe only what I see so I assume the 10/04/2019 press release was just preliminary paperwork and the 9/2/2020 is the first substantive submission to the FDA. When I see a positive entry in the "Results Returned after Quality Control Review" box of the study, I will become more optimistic - but I am not expecting the FDA to move quickly. This company and it's management deserves more scrutiny than praise.

I own this stock in 2 accounts and have successfully leveraged ups & downs while always maintaining in one. While I am now playing with house money, I have much more on the line than I care to lose. I only tell you this because I want you to know, even with skepticism rising, my ass is hanging out just like yours. So my GLTA is very sincere!

If we can apply HemoStyp to the share price, perhaps we can remedy this in less than 10 minutes.

Best to all

Question for anyone with EXPERIENCE with FDA approval process: Regardless of previous press release of PMA application submitted (10/04/2019) if study results were just submitted to FDA on 9/2/2020 is the actual FDA involvement in the process beginning only now?